KORU Medical Systems, Inc. (NASDAQ:KRMD) Given Consensus Rating of “Moderate Buy” by Analysts

KORU Medical Systems, Inc. (NASDAQ:KRMD) has received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $5.8750.

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 4th. Lake Street Capital raised their price objective on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Finally, Canaccord Genuity Group upped their target price on shares of KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th.

Institutional Investors Weigh In On KORU Medical Systems

A number of institutional investors and hedge funds have recently made changes to their positions in KRMD. Goldman Sachs Group Inc. grew its holdings in shares of KORU Medical Systems by 189.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock valued at $617,000 after purchasing an additional 158,914 shares during the last quarter. Acuitas Investments LLC bought a new stake in KORU Medical Systems in the second quarter worth $1,441,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in KORU Medical Systems by 23.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 82,631 shares of the company’s stock valued at $296,000 after buying an additional 15,714 shares during the period. Archon Capital Management LLC grew its stake in shares of KORU Medical Systems by 23.5% during the second quarter. Archon Capital Management LLC now owns 700,147 shares of the company’s stock valued at $2,507,000 after buying an additional 133,277 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of KORU Medical Systems by 52.1% in the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after buying an additional 3,478 shares during the period. Hedge funds and other institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Stock Performance

Shares of NASDAQ:KRMD traded down $0.16 during trading on Friday, hitting $5.65. 115,345 shares of the company were exchanged, compared to its average volume of 157,799. KORU Medical Systems has a 52-week low of $1.86 and a 52-week high of $6.61. The stock has a 50 day moving average of $5.30 and a 200 day moving average of $4.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92. The company has a market cap of $261.71 million, a PE ratio of -70.63 and a beta of 0.51.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.